Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT00080223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Study identification
- NCT ID
- NCT00080223
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Pirfenidone Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2003
- Primary completion
- Apr 29, 2015
- Completion
- Apr 29, 2015
- Last update posted
- Apr 16, 2017
2003 – 2015
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85006 | — |
| Not listed | Pomona | California | 91767 | — |
| Not listed | San Jose | California | 95119 | — |
| Not listed | New Haven | Connecticut | 06520 | — |
| Not listed | Sarasota | Florida | 34239 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Kailua | Hawaii | 96734 | — |
| Not listed | Lahaina | Hawaii | 96761 | — |
| Not listed | Nampa | Idaho | 83686 | — |
| Not listed | Elk Grove Village | Illinois | 60007 | — |
| Not listed | Boston | Massachusetts | 02118 | — |
| Not listed | West Roxbury | Massachusetts | 02132 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Huntington Station | New York | 11746 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | New York | New York | 10029-6574 | — |
| Not listed | Rochester | New York | 14620 | — |
| Not listed | Worthington | Ohio | 43085 | — |
| Not listed | Portland | Oregon | 97220 | — |
| Not listed | Portland | Oregon | 97227 | — |
| Not listed | Lancaster | Pennsylvania | 17601 | — |
| Not listed | Dallas | Texas | 75390-8503 | — |
| Not listed | Houston | Texas | 77005 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Provo | Utah | 84604 | — |
| Not listed | Annandale | Virginia | 22003 | — |
| Not listed | Bremerton | Washington | 98310 - 3349 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00080223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2017 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00080223 live on ClinicalTrials.gov.